Close Menu

NEW YORK (GenomeWeb) — Systaaq Diagnostic Products announced on Monday that it has received CE marking for its real-time PCR-based hepatitis B diagnostic.

The assay is designed to quantitate HBV DNA in serum or plasma to assist in the treatment of chronic HBV-infected patients receiving antiviral therapy, the Manassas, Virginia-based company said. Systaaq received CE marking for its RT-PCR-based hepatitis C quantitative assay in August.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Dec
02
Sponsored by
Sophia Genetics

This webinar will discuss how Moffitt Cancer Center has implemented a new capture-based application to accurately assess myeloid malignancies by detecting complex variants in challenging genes in a single experiment.